Bausch + Lomb (BLCO)

• Market cap: $5.38B
• 1 day: -0.85%
• 5 days: 0.8%
• 1 month: 10.31%
• 3 months: 22.11%
• 6 months: -0.33%
• Year to date: -15.61%
• 1 year: -2.94%
• 5 years: -24.05%
• 10 years: -24.05%
• Sector: Healthcare
• Industry: Medical Instruments & Supplies

About: Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Employees: 13,500

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

300% more funds holding in top 10

Funds holding in top 10: 1 [Q1] → 4 (+3) [Q2]

139% more call options, than puts

Call options by funds: $8.74M | Put options by funds: $3.66M

4% more repeat investments, than reductions

Existing positions increased: 27 | Existing positions reduced: 26

0.3% more ownership

Funds ownership: 10.46% [Q1] → 10.77% (+0.3%) [Q2]

7% less capital invested

Capital invested by funds: $535M [Q1] → $496M (-$38.6M) [Q2]

12% less funds holding

Funds holding: 106 [Q1] → 93 (-13) [Q2]

38% less first-time investments, than exits

New positions opened: 20 | Existing positions closed: 32

Research analyst outlook

5 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $13
• Avg. target: $15
• High target: $16

5 analyst ratings

• positive: 2 40%
• neutral: 3 60%
• negative: 0 0%

Morgan Stanley Patrick Wood	$13	Equal-Weight Maintained	1 Aug 2025
HC Wainwright & Co. Yi Chen	$16	Buy Maintained	31 Jul 2025
Wells Fargo Larry Biegelsen	$15	Equal-Weight Maintained	31 Jul 2025
Citigroup Joanne Wuensch	$15	Neutral Maintained	9 Jul 2025
Evercore ISI Group Vijay Kumar	$16	Outperform Maintained	8 Jul 2025